Medical Therapy

The Medical First Philosophy

At Hair Medicine Institute, medical therapy is not one option among several — it is the foundation of every treatment plan. This is not a marketing position. It is how the biology works.

Androgenetic alopecia is a chronic, progressive, hormonally driven process. The follicles on the top and front of your scalp are genetically programmed to shrink in response to dihydrotestosterone (DHT). Without intervention, this process continues indefinitely. Medical therapy addresses the root cause by blocking the hormonal signal that drives miniaturization and by stimulating follicles to produce thicker, longer hair.

Every other treatment modality — regenerative therapy, transplant surgery, laser therapy — builds on this foundation. A hair transplant without ongoing medical therapy is a depreciating asset: the transplanted hairs survive (they are DHT-resistant), but the surrounding native hair continues to miniaturize, and within a few years the result looks thin and unnatural. Regenerative treatments without medical therapy are boosting follicles that are still under hormonal assault. Medications are the shield. Everything else is the sword.

DHT-Blocking Therapy: The Cornerstone

Why DHT Matters

DHT is produced from testosterone by the enzyme 5-alpha reductase, which is active at the level of the hair follicle. When DHT binds to androgen receptors on susceptible follicles, it initiates a cascade that progressively shortens the growth phase, shrinks the dermal papilla, and reduces the diameter of each successive hair. Over time, a thick terminal hair becomes a fine, nearly invisible vellus hair. Blocking this process is the single most impactful thing you can do for your hair.

Dutasteride vs. Finasteride

Both medications work by inhibiting 5-alpha reductase, the enzyme that converts testosterone to DHT. The difference is scope: finasteride (1 mg) blocks only the Type II isoform of 5-alpha reductase, reducing circulating DHT by approximately 70%. Dutasteride (0.5 mg) blocks both Type I and Type II, reducing DHT by approximately 90%. Head-to-head studies have consistently shown dutasteride to be more effective than finasteride in increasing hair count and density.

The choice between the two is not one-size-fits-all — it depends on where you are in life. For men in their twenties and thirties who have not yet finished having children, we tend to be more conservative and start with finasteride. Finasteride has a short half-life (6–8 hours, cleared from the system in 1–2 days) and does not decrease sperm counts at the standard 1 mg dose. Dutasteride, by contrast, has a half-life of approximately 5 weeks and may slightly lower sperm counts, which makes it a less ideal first choice for men still planning a family.

Once a man is done having children, we often transition to oral dutasteride for more comprehensive DHT suppression. For younger men who want to be more aggressive without the systemic side-effect profile of oral dutasteride, there is an effective middle ground: topical dutasteride applied to the scalp combined with oral finasteride. This approach delivers more potent DHT suppression at the follicular level — where it matters most — while keeping systemic exposure lower than oral dutasteride alone. It offers the best of both worlds for motivated patients who want maximum efficacy with a more favorable risk profile.

Addressing the Side-Effect Conversation

The internet has amplified concerns about sexual side effects of 5-alpha reductase inhibitors to a degree that is disproportionate to the clinical data. This fear has prevented many men from starting medications that could meaningfully preserve their hair. Here is what the evidence actually shows:

In controlled clinical trials, approximately 2% of men taking oral finasteride 1 mg reported sexual side effects including decreased libido, erectile dysfunction, or ejaculatory changes. With oral dutasteride 0.5 mg, this rate is approximately 4%. These effects are reversible with discontinuation in the vast majority of cases.

We take patient concerns seriously — no one should be pressured into a medication they are uncomfortable with. But we also owe patients accurate information. The risk is real, it is small, and it is almost always reversible. For many men, the benefit of preserving their hair over decades significantly outweighs a low-probability, reversible side effect.

For patients who want to avoid any risk of systemic sexual side effects entirely, topical clascoterone is an option. Clascoterone works by blocking DHT from binding to the androgen receptor directly at the follicle, without reducing circulating DHT levels systemically. This means it has no sexual side-effect profile. It may be used alone in mild cases or layered on top of other therapies for enhanced local control. Topical formulations of finasteride or dutasteride offer another middle path: topical finasteride provides roughly 50% less systemic absorption than oral, which may further reduce side-effect incidence while still delivering clinically meaningful DHT reduction at the follicle.

Minoxidil: Stimulating Growth

Oral Minoxidil

Low-dose oral minoxidil has become a central component of our medical protocols. Originally developed as a blood pressure medication, minoxidil was reformulated topically in the 1990s after patients on the oral form noticed unexpected hair growth. More recently, prescribing has come full circle: low-dose oral minoxidil (typically 2.5–5 mg daily for men, 1.25–2.5 mg for women) provides consistent hair growth benefits without the inconvenience and scalp irritation associated with topical application.

Minoxidil works through a different mechanism than DHT blockers. It prolongs the anagen (growth) phase, increases hair shaft diameter, and enhances blood flow to the follicle via vasodilation and direct stimulation of dermal papilla cells. Because it operates independently of the androgen pathway, it is effective in both men and women and complements DHT-blocking therapy synergistically.

The most common side effect is hypertrichosis — increased body and facial hair — which is dose-dependent and reversible. Rarely, fluid retention can occur; patients who develop leg swelling or shortness of breath should contact their physician. Minoxidil does not cause sexual side effects.

Topical Minoxidil

Topical minoxidil (available over the counter in 2% and 5% concentrations, and by prescription in higher compounded strengths) remains an option for patients who prefer targeted application or want to minimize systemic exposure. The practical limitation is compliance: applying a solution or foam to the scalp once or twice daily, every day, indefinitely, is a routine that many patients struggle to maintain. Studies comparing twice-daily topical minoxidil to once-daily oral minoxidil show similar results, but even in those studies hair counts improved more with the oral form. For most patients, oral minoxidil is both simpler and more effective.

Women-Specific Considerations

The medical approach for women shares the same principles — block androgen activity, stimulate growth — but the specific medications differ based on hormonal context and life stage.

Premenopausal Women

For premenopausal women, the two primary anti-androgen options are spironolactone and finasteride. Spironolactone is the most commonly prescribed — it blocks the androgen receptor, preventing testosterone and DHT from acting on the follicle. It is well-tolerated at typical doses (100–200 mg daily), with menstrual irregularities and breast tenderness as the most common side effects. Spironolactone is contraindicated in pregnancy due to anti-androgen effects on a male fetus, but it has a short half-life, meaning it can be stopped quickly if a patient becomes pregnant.

Finasteride can also be used in premenopausal women who want more aggressive DHT suppression and who are committed to reliable contraception. In this context, finasteride is typically prescribed at 5 mg daily (a higher dose than the 1 mg used in men) to more effectively suppress DHT. For women who want maximum anti-androgen therapy, spironolactone and finasteride 5 mg can be combined. This is a more intensive approach, and patients must understand and formally consent to the teratogenic risk — pregnancy must be avoided during treatment and for at least one month after discontinuing finasteride.

Oral minoxidil is used in women at lower doses (1.25–2.5 mg daily) and is often the growth stimulant of choice because of its convenience and the difficulty of applying topical products to longer hair.

Postmenopausal Women

After menopause, the pregnancy concern becomes irrelevant, and the treatment landscape opens up significantly. For postmenopausal women, oral dutasteride is almost always our preferred anti-androgen. It provides the most comprehensive DHT suppression available — blocking both Type I and Type II 5-alpha reductase — and studies have demonstrated meaningful improvement in female pattern hair loss. Combined with oral minoxidil, this forms a potent and straightforward two-medication regimen that addresses both sides of the equation: hormonal blockade and growth stimulation.

Custom Compounding

At HMI, we frequently use custom compounding to simplify treatment regimens and improve long-term adherence. Compounding is not limited to topical formulations — we compound oral medications as well. A common example is a single all-in-one oral capsule combining minoxidil with dutasteride (or finasteride), reducing a patient’s daily pill burden to one medication instead of two.

On the topical side, compounded solutions can combine minoxidil at higher concentrations (5–8%) with finasteride or dutasteride, and sometimes additional agents like tretinoin (which enhances absorption) or ketoconazole (which provides mild anti-inflammatory and anti-androgenic benefit). Custom compounding — whether oral or topical — allows us to match the treatment to the patient rather than forcing the patient to fit a commercial product. Fewer pills, fewer bottles, clearer routines — and better adherence as a result.

Setting Realistic Expectations

Medical therapy requires patience. Because hair follicles cycle through growth phases lasting months to years, visible results typically take a minimum of 3–6 months, with the full effect becoming apparent at 12–18 months. This is not a reflection of whether the medication is working — it is a reflection of the biology of the hair cycle.

Some patients experience an increase in shedding during the first 4–8 weeks of treatment, particularly with minoxidil. This is commonly called the “dread shed” and is actually a positive sign: it indicates that the medication is pushing weakened, resting hairs out of the follicle to make way for new, healthier growth. It is not a reason to stop treatment.

These are long-term, typically indefinite medications. The analogy I use with patients is blood pressure: if you stop taking your blood pressure medication, your blood pressure is no longer controlled. Hair loss medication works the same way — it works while you use it. Androgenetic alopecia does not resolve on its own, and when effective therapy is discontinued, the protective benefit stops and miniaturization resumes. The best plan is one you can realistically maintain for years — which is why we emphasize simplicity, tolerability, and custom compounding to reduce pill burden.

How Medical Therapy Connects to the Bigger Picture

Medical therapy is the step that stabilizes the disease process and creates the biological conditions for everything that follows. It is the non-negotiable starting point. For patients who want to go further, regenerative therapy can augment and accelerate the response. For patients who eventually pursue hair transplantation, ongoing medical therapy protects both the transplanted and native hair, ensuring the surgical result holds up over time. For patients who come to HMI specifically for a transplant, medical therapy is required (unless contraindicated) and remains essential after surgery to maintain results.

For patients who choose medical therapy alone, that is a completely valid and often highly effective approach. Most of our patients are managed primarily with medication, and most achieve meaningful stabilization and improvement with medication alone. The medication foundation is what makes every other intervention — regenerative or surgical — work better and last longer.

Next Steps

If you are experiencing hair thinning or loss, the most impactful decision you can make is starting the right medical therapy as early as possible. Every month of delay means more follicles that cross from “treatable” to “lost.” At Hair Medicine Institute, every new patient receives a comprehensive evaluation with dermoscopy, relevant laboratory workup, and a personalized medication plan designed for long-term adherence. The HMI membership program makes ongoing care financially sustainable — with monthly fees that accrue as credit toward any future procedure.

 

 

Regenerative Therapy

What Regenerative Therapy Means at HMI

Regenerative therapy encompasses treatments designed to improve the biological environment of the scalp — reducing inflammation, stimulating new blood vessel formation, and delivering growth factors and signaling molecules to the follicular unit. Some of these treatments are performed in the office. Others, like low-level laser therapy, are done at home. What they share is a common purpose: enhancing and accelerating the results of medical therapy.

This distinction matters. Many clinics market PRP and exosome treatments as standalone solutions for hair loss. At HMI, we are direct about the hierarchy: medical therapy is the load-bearing pillar of any hair loss treatment plan. Regenerative therapies are genuinely beneficial adjuncts that can improve outcomes for patients already on a solid medication foundation — but they are not a substitute for the daily medications that block DHT and stimulate follicular growth. A patient who refuses medical therapy but wants regenerative treatments alone is unlikely to see meaningful, durable improvement.

In-Office Regenerative Treatments

HMI offers two tiers of in-office regenerative treatment, tailored to patient goals, pain tolerance, and budget.

Baseline Protocol: Fractional Laser + Peptide Delivery

The foundation of our in-office protocol is a two-step sequence with minimal discomfort. It begins with fractional non-ablative laser treatment using the Lumenis M22 ResurFX platform at 1565nm. This is the same core wavelength used in the Folix system — the first FDA-cleared laser marketed specifically for hair restoration. The Lumenis and Folix platforms deliver biologically equivalent laser energy; at HMI, we provide the same regenerative stimulus using a physician-grade, multipurpose system.

The fractional laser delivers columns of energy into the dermis, creating controlled micro-thermal zones without disrupting the skin surface. This accomplishes several things simultaneously: it stimulates angiogenesis (new blood vessel formation) and vascular remodeling around the hair follicle, improving oxygen and nutrient delivery. It activates heat shock proteins (HSPs) within scalp cells, which protect cells under stress, improve mitochondrial resilience, and enhance cellular repair signaling. And it creates micro-channels in the scalp that significantly enhance the penetration of topically applied biologics in the next step.

Immediately following the laser, a needle-free ultrasound device (Juvasonic) is used to drive the Xtressé FR concentrate deep into the scalp through the open micro-channels. The Xtressé FR concentrate contains BPC-157 (a peptide with anti-inflammatory and tissue-repair properties), zinc thymulin (which modulates the hair cycle and supports follicular immune function), and GHK-Cu (a copper peptide that promotes collagen synthesis and tissue remodeling). The ultrasound energy enhances delivery well beyond what topical application alone could achieve.

This baseline protocol is well-tolerated — the laser produces a mild heat sensation, and the ultrasound step is painless. Most patients do not require any anesthesia.

Advanced Protocol: Microneedling with Exosomes

For patients who want to be more aggressive and are comfortable with moderate discomfort, we offer microneedling with Xvie exosome application. This is an add-on to the baseline protocol, not a replacement for it.

Microneedling creates controlled micro-injury across the treatment area, triggering the body’s wound-healing cascade and releasing endogenous growth factors including VEGF, PDGF, IGF-1, and FGF. Exosomes — nanoscale extracellular vesicles derived from amniotic fluid — are applied immediately after needling, delivering a concentrated payload of growth factors, cytokines, and signaling molecules directly into the scalp through the freshly created channels. Unlike PRP, exosomes provide cell-to-cell signaling instructions, not just growth factor delivery, helping orchestrate a more coordinated regenerative response.

Microneedling is more uncomfortable than the laser protocol. At HMI, we perform a ring block with buffered lidocaine prior to microneedling to ensure the treatment is tolerable. Patients should expect moderate discomfort during the block itself, after which the microneedling procedure is well-managed.

PRP: An Alternative to Microneedling with Exosomes

Platelet-rich plasma (PRP) remains a viable regenerative option and serves as an alternative to microneedling with exosomes — not an addition to it. There is no need to do both. PRP is prepared by drawing a small volume of the patient’s blood and centrifuging it to concentrate the platelets, which contain growth factors including PDGF, VEGF, IGF-1, and EGF. At HMI, PRP is concentrated to approximately 5–7× baseline platelet levels, aligning with published literature on optimal therapeutic concentration.

PRP is injected directly into areas of thinning, where the concentrated growth factors stimulate dermal papilla cells, promote angiogenesis, prolong the anagen phase, and reduce perifollicular inflammation. It is a reasonable choice for patients who prefer an autologous (derived from their own body) approach or who have had good results with PRP in the past.

At-Home Regenerative Therapy: Low-Level Laser Therapy (LLLT)

Not all regenerative therapy requires a trip to the office. Low-level laser therapy (LLLT) is a home-based treatment that uses low-energy light to stimulate hair follicles, and it is a genuinely useful component of a comprehensive hair restoration plan.

At HMI, we recommend the Revian Red dual-wavelength LLLT cap. After evaluating multiple devices on the market, we prefer the Revian for several practical reasons. First, it is the most comfortable cap we have tried — it actually stays on your head and allows you to walk around during treatment, which is not true for most competing devices. Second, it requires only 10 minutes of daily use, which makes compliance realistic. Third, it includes built-in compliance monitoring that allows Dr. Hawkins to track whether patients are actually using the device — a meaningful feature, because the biggest limitation of any home device is whether people use it consistently.

The clinical data support the Revian as well. Studies have demonstrated improvements of up to 25 hairs per square centimeter at 4 months of use. Additionally, case reports have shown potential effectiveness in scarring alopecias including CCCA and lichen planopilaris, which is particularly relevant given how few treatments meaningfully address those conditions.

The Revian cap retails for $1,500. Patients who order through Dr. Hawkins receive a $500 discount, bringing the cost to $1,000. Given that this is a one-time purchase for a device used daily over years, the per-use cost is minimal.

Honest Assessment of the Evidence

Transparency about the evidence base is part of how we build trust with patients. Here is where things stand:

PRP has the most published clinical data of any regenerative hair treatment. Multiple randomized controlled trials have demonstrated modest but statistically significant improvements in hair density and thickness. Results are variable across studies, in part because there is no standardized preparation protocol, and outcomes depend heavily on platelet concentration, injection technique, and patient selection.

Exosomes are scientifically compelling, with strong mechanistic rationale and encouraging preclinical data. However, the human clinical trial data are still early. Exosomes are not currently FDA-approved for hair loss specifically. Our clinical experience supports their benefit, but we cannot yet point to the same depth of controlled trial evidence that exists for medications like dutasteride or minoxidil.

LLLT has a solid evidence base. A systematic review found that 10 of 11 clinical trials demonstrated significant improvement in androgenetic alopecia compared to controls. The Revian specifically has published data supporting its efficacy. The magnitude of benefit is modest compared to first-line medications but is additive and comes with virtually no side effects.

Peptide serums and fractional laser have solid mechanistic underpinnings — the biological pathways they target are well-established — but controlled trial data specific to hair restoration remain limited.

The honest framing: these treatments work best as part of an integrated protocol, layered on top of evidence-based medical therapy. They are not miracle cures. They are not replacements for medication. They are biological amplifiers that can meaningfully improve outcomes for patients who are already doing the most important thing — taking their medications consistently.

Who Benefits Most?

Regenerative therapy is most impactful for patients who are already on medical therapy and want to accelerate or enhance their results. Partial responders to medication — patients who have stabilized but haven’t achieved the density improvement they were hoping for — are ideal candidates. Patients preparing for hair transplant surgery also benefit significantly: pre-operative regenerative treatment improves scalp vascularity, may enhance graft survival, and can reduce post-operative shock loss.

Regenerative therapy is not the right starting point for someone who has not yet initiated medical therapy. If a patient is not willing or able to take DHT-blocking and growth-stimulating medications, regenerative treatments alone are unlikely to meaningfully change their trajectory. We are candid about this during consultation.

What to Expect During an In-Office Session

A baseline regenerative session (fractional laser + Juvasonic peptide delivery) takes approximately 45–60 minutes. Pain is minimal — the laser produces a mild heat sensation, and the ultrasound step is painless. No anesthesia is typically needed, and patients return to normal activities immediately. The scalp may appear mildly pink for 12–24 hours.

Adding microneedling with exosomes extends the session and requires a ring block with buffered lidocaine for comfort. Total time is approximately 60–90 minutes. For patients receiving PRP instead, a blood draw is performed at the beginning so the sample can be processed during the laser portion. Patients should avoid heavy exercise and excessive sweating for 24 hours after any in-office session.

Regenerative Therapy and Surgical Planning

For patients who are moving toward hair transplant surgery, regenerative therapy serves a specific pre-operative purpose. Improving the scalp’s vascular environment before surgery enhances graft survival — transplanted follicles depend on rapid revascularization to take hold in the recipient site. Pre-operative regenerative treatment also thickens existing native hair, which can reduce the total number of grafts needed and improve the overall cosmetic result.

Post-operatively, regenerative treatments can accelerate the recovery timeline, reduce shock loss (temporary shedding of native hairs in the transplanted area), and support the long-term health of both transplanted and native follicles. At HMI, regenerative therapy and surgery are treated as components of a single biological strategy, not isolated services.

Treatment Frequency and Cost

In-office regenerative treatments are typically performed in a series spaced 4–6 weeks apart, followed by maintenance sessions every 3–6 months. Results are gradual and complement the medical therapy timeline — most patients begin to notice incremental improvement after 2–3 sessions.

In-office sessions typically range from $800–$1,200 depending on the modalities included. We are upfront about this because we believe patients deserve cost transparency. The HMI membership program ($45/month, month-to-month) was designed in part to make regenerative therapy more accessible: 100% of monthly fees accrue as procedure credit, which can be applied toward regenerative treatment sessions or banked toward future transplant surgery. Members also do not pay separately for their follow-up visits — those are included in the membership.

Next Steps

If you are already on medical therapy and want to explore whether regenerative treatments — in-office, at-home, or both — could enhance your results, a consultation can help determine the right combination for your specific situation. At HMI, regenerative treatments are always integrated into a broader plan — never sold as isolated procedures.

 

 

The HMI Membership Program

Why a Membership Model?

Androgenetic alopecia is a chronic, progressive condition. It does not resolve on its own, and there is no one-time cure. Effective management requires ongoing medical therapy (typically indefinite), periodic monitoring and treatment adjustments, and for many patients, regenerative treatments or eventual surgical restoration. This is not a one-visit problem — it is a long-term relationship between patient and physician.

The HMI membership program was designed to align the financial structure of that relationship with its clinical reality. Rather than a series of large, unpredictable costs for individual procedures, the membership provides a steady, manageable monthly investment that accrues as credit toward the treatments most patients will eventually want or need — while also including all follow-up visits and active treatment monitoring at no additional charge.

The Compliance Problem — and Why It Matters

Hair loss medications work. That is well-established. The real challenge is getting patients to stick with them long enough to see and sustain results. A study on patients starting topical minoxidil found that by six months, only 20% were still using it. The medications did not fail those patients — the system around them did.

Without regular monitoring, standardized photography, and someone actively checking in, most patients do not realize their treatment is working. Hair changes are gradual — you look in the mirror every day, and incremental improvement is almost invisible in real time. Without documented before-and-after comparisons and a physician reviewing progress at regular intervals, patients lose confidence in the plan and stop. By the time they realize the medication was working, they have lost months of progress.

At HMI, we function as your personal trainer for your hair. Members receive active, ongoing management — not just a prescription and a handshake. We track whether you have received your medications, when you need to be seen next, whether you are experiencing side effects, and whether your dose needs adjustment. We reach out proactively, not reactively. Non-members still receive reminders and good care at their visits, but between visits it is ultimately on them. Members get a team that is actively making sure they stick to the plan.

How It Works

The structure is straightforward:

$45 per month, month-to-month. There is no long-term contract. You can pause or cancel at any time. This is intentional — we want patients to stay because the care is valuable, not because they are locked into an agreement.

All follow-up visits are included. Members do not pay separately for follow-up appointments. This alone makes the membership financially advantageous: a standard follow-up visit at HMI is $275. At two visits per year (which is the typical monitoring cadence), that is $550 out of pocket for non-members. Twelve months of membership is $540 — meaning the membership is actually less expensive than paying per visit, before you even factor in the accrued procedure credit.

100% of monthly fees accrue as procedure credit. Every dollar you pay in membership fees becomes a dollar of credit toward any HMI procedure — regenerative treatment sessions, hair transplant surgery, or other in-office services. This is not a discount on a marked-up price. It is actual credit.

$2,500 cap on accrued credit. Credit accumulates until it reaches $2,500, at which point additional monthly fees no longer add to the balance. At $45/month, this cap is reached at approximately 4.5 years.

The Math

After 12 months of membership, you have $540 in accrued credit — and you have paid less than you would have for two standard follow-up visits. That credit is enough to offset the cost of a regenerative treatment session or to begin banking toward a larger procedure. After 24 months, you have $1,080. After approximately 55 months, you reach the $2,500 cap — a meaningful credit toward a hair transplant procedure.

Put differently: a patient who joins the membership knowing they may want a transplant in 3–4 years will have accumulated $1,620–$2,160 in credit by the time they are ready — money that reduces their out-of-pocket surgical cost while ensuring they have been under continuous, actively managed medical care throughout.

What Members Get

Beyond visit inclusion and credit accrual, HMI membership includes active treatment monitoring and compliance support — the personal trainer model described above. We check in on your medication status, track your progress with standardized photography, proactively identify when a dose adjustment or therapy change is needed, and make sure you do not fall off your treatment plan. Members also have access to member-only pricing on hair care products and supplements carried by the practice.

This is not concierge medicine in the traditional sense — it is structured, proactive chronic disease management. The same kind of ongoing engagement that makes the difference between a patient who stays on therapy for years and sees sustained improvement, and a patient who quietly stops after four months because nobody was watching.

Who This Is For

The membership is the default recommendation for any patient with androgenetic alopecia who plans to be under HMI’s care long-term. That includes the patient who is starting medical therapy alone and needs monitoring over time. The patient who wants to add regenerative treatments to their regimen. The patient who is building toward eventual transplant surgery. And the patient who is not sure what they will want in a year but knows they want to keep their options open.

In practice, the vast majority of HMI patients benefit from membership because androgenetic alopecia is by definition a long-term condition. Even if your only current treatment is a daily medication, your condition should be monitored, your therapy may need adjustment, and the credit you accumulate provides flexibility for future decisions.

What the Membership Is Not

The membership is not a subscription box. It is not a concierge gimmick. It is not a requirement for being seen at HMI — patients can choose not to participate and pay for services individually at standard rates.

What it is: a structured way to make the long-term financial commitment of managing a chronic condition more manageable, with tangible returns in the form of included visits, procedure credit, and active compliance support. It rewards consistency — the same consistency that makes medical therapy effective.

Common Questions

“I’m only on medications right now. Do I need a membership?” You do not need it, but you benefit from it — and it likely saves you money. Your medications require monitoring, your condition requires periodic reassessment, and your follow-up visits are included. Even if you never use a single dollar of procedure credit, you are paying less than you would for standard per-visit care while receiving more active management.

“Can I use my credit toward a hair transplant?” Yes. Accrued credit applies to any HMI procedure, including FUE and FUT hair transplant surgery. Many patients join the membership years before they are surgical candidates, accumulating credit during the medical stabilization phase so that when the time comes, a significant portion of the surgical cost is already covered.

“What happens if I cancel?” Accrued credit is available as long as your membership is active. If you cancel and later rejoin, credit does not carry over — it resets. This is another reason the month-to-month, no-contract structure matters: the bar to staying is low, and the incentive to continue is built into the credit accumulation.

What Membership Looks Like in Practice

Consider a typical patient: a 32-year-old man who starts at HMI with early Norwood III hair loss. He begins dutasteride and oral minoxidil, joins the membership, and is actively monitored with regular check-ins and standardized photography. After 6 months, his hair has stabilized and he is seeing early thickening — something he might not have noticed without the side-by-side photos his care team reviews with him. He decides to add a regenerative treatment series; his accrued credit offsets a portion of the cost. At 18 months, he is considering a transplant to restore his temples. He has $810 in credit banked and continues to accrue. By the time he proceeds with surgery at month 30, he has $1,350 in credit — money that reduces his out-of-pocket cost while ensuring he has been under continuous, actively managed medical care throughout.

This is the model working as designed: consistent care, proactive monitoring, accumulating financial benefit, and a long-term plan that adapts as the patient’s needs evolve.

How the Membership Fits the HMI Model

Medical therapy is the foundation — the non-negotiable starting point. Regenerative therapy enhances results for patients who want to go further. Transplant surgery restores hair in areas that medication and regenerative treatments cannot reach. The membership program ties all of it together, making the entire long-term care model financially sustainable and accessible. These four elements — medical therapy, regenerative therapy, surgical restoration, and the membership — form a coherent system designed around the clinical reality that hair loss is a chronic condition requiring ongoing, adaptive management.

The alternative — sporadic visits, intermittent treatment, no compliance tracking, and large unpredictable costs — works against both the biology and the patient’s best interests. The membership exists to make the better approach the easier approach.

Next Steps

If you are starting treatment at HMI or considering transitioning to ongoing care, the membership is the most straightforward way to engage with the practice long-term. There is no commitment beyond the current month, every dollar accrues as credit toward your future care, and all follow-up visits are included. Your consultation is the right time to discuss whether the membership makes sense for your specific treatment plan and goals.